Anti-obesity effects of gallic acid

According to foreign literature, gallic acid was first made by Scherrer (1786). However, it was clearly documented in ancient China long before this. For example, in Li Ting's "Introduction to Medicine" (1575) of the Ming Dynasty, the process of obtaining gallic acid from pentospermum by fermentation is recorded. In the book, it is said that "the coarse powder of five times the seeds, and alum, and the curve and even, such as for the wine song, such as porcelain cover without wind, waiting for the raw white out. The "Compendium of Materia Medica" volume 39 has "see the long frost on the medicine, the medicine has been completed". Here, the words "raw white" and "long cream" both mean gallic acid production, which was the first organic acid produced in the world, two hundred years before Scherrer's discovery.

Microbial post-fermentation enhances the gallic acid content of tea leaves

It is well documented that older teas containing gallic acid (GA) do have health benefits.

The post-fermentation process of the tea leaves has increased the GA and tea polysaccharide content significantly, making the post-fermented tea broth sweeter and smoother than before fermentation.

Hypotensive effects of gallic acid.

GA can control hypertension in an animal model of essential hypertension (16 weeks in spontaneously hypertensive rats) by modulating the oxidative stimulus response.GA reduces the elevation of systolic blood pressure in the treatment of hyperlipidaemia (SHR) by inhibiting the renin-angiotensin || system and vasoconstriction.

In addition, GA reduced aortic wall thickness and body weight in SHR rats. Studies have shown that GA may prevent hyperlipidaemia, hypertension and left ventricular hypertrophy (LVH) induced by streptozotocin.

Anti-obesity effects of gallic acid.

An imbalance between excessive energy intake and consumption can lead to obesity, which is associated with chronic diseases such as non-insulin-dependent diabetes, hypertension and hyperlipidaemia.

Adipogenesis is a differentiation process by which undifferentiated adipose precursor cells are transformed into fully differentiated adipocytes, i.e. adipocytes.

Adipogenesis is known to be closely related to the etiology of obesity, the metabolic disorder associated with obesity.

The anti-obesity effect of GA was investigated experimentally and found to have pancreatic lipase inhibitory activity in vitro.

The results showed that GA promotes the anti-obesity effect of BTE as an active ingredient by inhibiting pancreatic lipase activity.

In an in vitro screen, GA showed inhibitory effects on lipid droplet formation and triglyceride accumulation.

Obese mice treated with GA reduced the body weight of the animals.

In the presence of obesity, excessive secretion of obesity hormones can lead to disruption of hypothalamic function and GA can do this by inhibiting obesity hormones.

Obesity is considered to be a state of low inflammation and inflammation is considered to be the cause or result of obesity.

At a dose of 8mg/kg, GA inhibits elevated serum triglycerides, LDL and very low density lipoproteins with significant effect.

GA is a potent compound that can regulate body weight in obese mice through diet.